Edition:
United States

STAAR Surgical Co (STAA.OQ)

STAA.OQ on NASDAQ Stock Exchange Global Market

12.95USD
20 Oct 2017
Change (% chg)

$0.50 (+4.02%)
Prev Close
$12.45
Open
$12.65
Day's High
$12.95
Day's Low
$12.40
Volume
40,243
Avg. Vol
27,499
52-wk High
$13.88
52-wk Low
$7.40

Chart for

About

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in... (more)

Overall

Beta: 1.09
Market Cap(Mil.): $532.36
Shares Outstanding(Mil.): 41.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 33.06 16.52
EPS (TTM): -- -- --
ROI: -- 13.87 11.32
ROE: -- 16.68 15.18

BRIEF-Staar surgical appoints Scott Barnes, M.D. as chief medical officer

* Staar surgical appoints Scott Barnes, M.D. as chief medical officer Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Staar Surgical names Deborah Andrews as CFO

* Deborah Andrews, interim CFO, has agreed to resume her role as Chief Financial Officer for company​ Source text for Eikon: Further company coverage:

Sep 28 2017

BRIEF-STAAR Surgical, Seoul/Busan BalGeunSeSang eye clinic announce strategic cooperation agreement

* STAAR Surgical and Seoul/Busan Balgeunsesang eye clinic announce strategic cooperation agreement

Aug 15 2017

BRIEF-Staar Surgical Q2 loss per share $0.02

* Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 02 2017

Staar Surgical to pay $7 million in investor suit over FDA violations

Staar Surgical Co, a manufacturer of implantable lenses to correct vision problems, has agreed to pay $7 million to resolve a lawsuit claiming the company misled investors about its compliance with Food and Drug Administration regulations.

Jun 21 2017

BRIEF-Staar Surgical files for potential mixed shelf offering

* Staar Surgical Co files for potential mixed shelf offering of up to $200 million - SEC filing

May 11 2017

BRIEF-STAAR Surgical announces CE Mark approval for the EVO+ visian ICL with aspheric (EDOF) optic

* STAAR Surgical announces CE Mark approval for the EVO+ Visian ICL with aspheric (EDOF) optic

May 11 2017

BRIEF-Staar Surgical reports Q1 sales $20.4 million

* Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S

May 03 2017

Earnings vs. Estimates